Table A1.
Baseline characteristics according to serum lactate levels (mmol/L).
| Overall Population (n = 360) | IPTW Population (n = 1083) | |||||||
|---|---|---|---|---|---|---|---|---|
| Lactate ≤ 2.5 | 2.5 ≤ Lactate < 4.0 | Lactate > 4.0 | p Value | Lactate ≤ 2.5 | 2.5 ≤ Lactate < 4.0 | Lactate > 4.0 | p Value | |
| (n = 241) | (n = 80) | (n = 39) | (n = 359) | (n = 361) | (n = 363) | |||
| Age | 59.6 ± 11.4 | 61.5 ± 13.4 | 61.4 ± 12.5 | 0.373 | 60.1 ± 11.4 | 59.5 ± 13.5 | 60.1 ± 13.6 | 0.967 |
| Male | 205 (85.1) | 63 (78.8) | 26 (66.7) | 0.017 | 293 (81.6) | 297 (82.5) | 301 (82.9) | 0.968 |
| Body mass index, kg/m² | 24.8 ± 3.3 | 24.4 ± 3.6 | 23.7 ± 4.6 | 0.183 | 24.6 ± 3.3 | 24.8 ± 3.7 | 25.0 ± 5.8 | 0.215 |
| Current smoker | 106 (44.0) | 30 (37.5) | 15 (38.5) | 0.534 | 150 (41.6) | 152 (42.0) | 160 (44.1) | 0.916 |
| Hypertension | 104 (43.2) | 40 (50.0) | 21 (53.9) | 0.322 | 166 (46.1) | 165 (45.8) | 175 (48.3) | 0.915 |
| Diabetes mellitus | 51 (21.2) | 27 (33.8) | 17 (43.6) | 0.003 | 96 (26.8) | 97 (26.9) | 106 (29.1) | 0.900 |
| Dyslipidemia | 51 (21.2) | 16 (20.0) | 3 (7.7) | 0.142 | 80 (22.2) | 66 (18.4) | 21 (5.8) | 0.001 |
| History of percutaneous coronary intervention | 17 (7.1) | 11 (13.8) | 2 (5.1) | 0.128 | 32 (8.9) | 30 (8.3) | 31 (8.5) | 0.987 |
| History of cerebrovascular accident | 6 (2.5) | 6 (7.5) | 2 (5.1) | 0.122 | 10 (2.7) | 31 (8.5) | 21 (5.8) | 0.150 |
| Clinical presentation | ||||||||
| NSTEMI | 85 (35.3) | 25 (31.3) | 10 (25.6) | 0.449 | 120 (33.5) | 122 (33.8) | 108 (29.8) | 0.765 |
| STEMI | 156 (64.7) | 55 (68.8) | 29 (74.4) | 0.449 | 239 (66.5) | 239 (66.2) | 255 (70.2) | 0.765 |
| Laboratory findings | ||||||||
| NT-proBNP, pg/mL | 186.4 (51.8–846.8) | 243.4 (72.7–1062.0) | 196.7 (45.7–1360.0) | 0.106 | 196.9 (53.6–926.3) | 219.8 (70.3–849.4) | 137.4 (40.5–1022.0) | 0.381 |
| White blood cell, ×103/μL | 11.1 (8.9–13.4) | 13.5 (10.6–16.9) | 17.7 (12.9–23.2) | <0.001 | 11.2 (8.9–13.4) | 13.5 (10.9–17.1) | 17.7 (14.0–21.9) | <0.001 |
| Hemoglobin, g/dL | 14.6 (13.2–15.6) | 14.3 (13.1–15.7) | 13.8 (12.3–15.0) | 0.034 | 14.4 (13.0–15.5) | 14.7 (13.4–15.9) | 13.9 (13.0–15.4) | 0.188 |
| Platelet ×103/μL | 225.0 (194.0–263.0) | 218.0 (191.0–250.0) | 254.0 (19.0–273.0) | 0.115 | 227.0 (195.0–269.0) | 216.0 (190.0–249.0) | 262.0 (210.0–284.0) | 0.010 |
| Peak CK-MB, ng/mL | 92.0 (29.7-214.7) | 126.2 (39.0-256.1) | 288.7 (86.3-500.0) | <0.001 | 91.0 (28.5-214.1) | 126.1 (47.0-257.6) | 264.0 (69.0-495.7) | <0.001 |
| Concomitant medications | ||||||||
| Aspirin | 239 (99.2) | 78 (97.5) | 39 (100.0) | 0.365 | 356 (99.0) | 352 (97.5) | 363 (100.0) | 0.194 |
| P2Y12 inhibitor | 237 (98.3) | 78 (97.5) | 39 (100.0) | 0.607 | 353 (98.4) | 351 (97.4) | 363 (100.0) | 0.225 |
| Beta blocker | 216 (89.6) | 71 (88.8) | 33 (84.6) | 0.652 | 324 (90.3) | 321 (89.0) | 314 (86.5) | 0.643 |
| ACE inhibitor or ARB | 193 (80.1) | 63 (78.8) | 30 (76.9) | 0.889 | 287 (80.0) | 288 (79.9) | 272 (74.9) | 0.545 |
| Statin | 228 (94.6) | 76 (95.0) | 36 (92.3) | 0.819 | 341 (95.0) | 346 (95.9) | 338 (93.0) | 0.607 |
Data are presented as n (%), mean ± standard deviation, or median (interquartile range). ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, CK-MB = creatine kinase-myocardial band, IPTW = inverse probability of treatment weighting, NT-proBNP = N-terminal prohormone of brain natriuretic peptide, STEMI = ST-segment elevation myocardial infarction, NSTEMI = non-ST-segment elevation myocardial infarction.